Last reviewed · How we verify

NCT05143567

Hemostasis and Inflammation in COVID-19 Patients With Venous and Arterial Thrombotic Complications

Completed NA Last updated 18 November 2023
What this trial tests

NA trial testing standard of care anticoagulation in absence of thrombotic complications in Venous Thromboembolism in 150 participants. Completed in 23 July 2023.

Timeline
1 November 2021
Primary endpoint
23 July 2023
23 July 2023

Quick facts

Lead sponsorRyazan State Medical University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposeother
Enrollment150
Start date1 November 2021
Primary completion23 July 2023
Estimated completion23 July 2023
Sites1 location across Russia

Drugs / interventions tested

Conditions studied

Sponsor

Ryazan State Medical University

Who can join

Adults 18 to 80, any sex, with Venous Thromboembolism or covid19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is aimed at assessing the role of the activity of high-risk markers of thrombotic events (MCP-1, MIP1α, IP-10, phosphatedylserine, calreticulin) on the development of thrombotic complications in patients with COVID -19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

Other Ryazan State Medical University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05143567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing